Asia Pacific Herald
SEE OTHER BRANDS

The latest news from Asia and the Pacific

Asia Pacific Herald: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Pacific Herald.

Press releases published on June 2, 2025

Xunlei Closes Acquisition of Hupu

Xunlei Closes Acquisition of Hupu

SHENZHEN, China, June 02, 2025 (GLOBE NEWSWIRE) -- Xunlei Limited ("Xunlei" or the "Company") (Nasdaq: XNET), a leading technology company providing distributed cloud services in China, today announced that it has closed the acquisition of Shanghai …

Webus Signs up to $300 Million XRP Treasury Management Agreement with Top-Tier Manager Samara Alpha, Making a Major Step in Its XRP Treasury Strategy

Webus Signs up to $300 Million XRP Treasury Management Agreement with Top-Tier Manager Samara Alpha, Making a Major Step in Its XRP Treasury Strategy

Hangzhou, CHINA, June 02, 2025 (GLOBE NEWSWIRE) -- Webus International Limited (“Webus” or the “Company”) (NASDAQ: WETO), a leading provider of AI-driven mobility solutions specializing in premium, customizable chauffeur services worldwide, today announced …

Aventis Energy Announces Appointment of Michael Mulberry to the Board of Directors

Aventis Energy Announces Appointment of Michael Mulberry to the Board of Directors

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF), is pleased to announce that Mr. Michael Mulberry has been appointed to the board of directors of the …

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is the most rapidly increasing HNSCC in the US VERSATILE-003 …

Animal Nutrition Chemicals Market Size Worth USD 77.32 Billion by 2031, Rising Requirement for High Quality and Nutritious Animal Feed Fuels the Demand | The Insight Partners

Animal Nutrition Chemicals Market Size Worth USD 77.32 Billion by 2031, Rising Requirement for High Quality and Nutritious Animal Feed Fuels the Demand | The Insight Partners

US …

Frozen Food Market Size to expected to reach US$ 444.22 Billion by 2031, Rising Demand for Convenience Food Drives Growth | The Insight Partners

Frozen Food Market Size to expected to reach US$ 444.22 Billion by 2031, Rising Demand for Convenience Food Drives Growth | The Insight Partners

US …

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a …

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …

Amerigo Announces Board Appointment

Amerigo Announces Board Appointment

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; ARREF:OTC) (“Amerigo” or the “Company”) is pleased to announce the appointment of Ignacio Cruz to the Company’s board of directors. Ignacio Cruz is a Civil …

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. …

Emerita Provides Comments on Announcement Approving Development of Aznalcollar Project, Spain

Emerita Provides Comments on Announcement Approving Development of Aznalcollar Project, Spain

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) provides comments with respect to the announcement made on May 30, 2025 by the Minister of Energy and Mines of Andalucia, …

SAP positioned as the Leader in the 2025 SPARK Matrix: Digital Twin of an Organization Solution by QKS Group

SAP positioned as the Leader in the 2025 SPARK Matrix: Digital Twin of an Organization Solution by QKS Group

Middleton, Massachusetts, June 02, 2025 (GLOBE NEWSWIRE) -- The QKS Group SPARK Matrix™ provides competitive analysis and ranking of the leading Digital Twin of an Organization Solution vendors.   SAP, with its comprehensive technology for the Digital Twin …

Dynacor Group Declares June 2025 Dividend

Dynacor Group Declares June 2025 Dividend

MONTRÉAL, June 02, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) ("Dynacor" or the "Corporation") announced its monthly dividend payment for June 2025 in the amount of C$0.01333 per common share which will be payable on June 18, 2025, to …

Groupe Dynacor déclare son dividende pour juin 2025

Groupe Dynacor déclare son dividende pour juin 2025

MONTRÉAL, 02 juin 2025 (GLOBE NEWSWIRE) -- Groupe Dynacor Inc. (TSX : DNG) (« Dynacor » ou la « Société ») a le plaisir d’annoncer la déclaration de son dividende mensuel pour le mois de juin 2025 au montant de 0,01333$CA par action qui sera payé le 18 …

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be …

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next- …

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., …

Aura Minerals Agrees to Acquire the Mineração Serra Grande Gold Mine in Goiás, Brazil

Aura Minerals Agrees to Acquire the Mineração Serra Grande Gold Mine in Goiás, Brazil

ROAD TOWN, British Virgin Islands, June 02, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (TSX: ORA, B3: AURA33 and OTCQX: ORAAF) (“Aura” or the “Company”) is pleased to announce that Aura, AngloGold Ashanti plc (“AngloGold”) and a wholly owned subsidiary of …

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury

Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord …

Cancer mRNA Vaccine Clinical Trials FDA Approval mRNA Therapies Clinical Advances Insight

Cancer mRNA Vaccine Clinical Trials FDA Approval mRNA Therapies Clinical Advances Insight

Delhi, June 02, 2025 (GLOBE NEWSWIRE) -- mRNA cancer vaccines approach clinical maturity, the commercial landscape surrounding them is rapidly changing. Over 60 candidates in the works, with a few in Phase III clinical trials, the industry is increasingly …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service